parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in retinal pigment epithelial cells	0.75
chemistry Open Targets	compounds already reach it: cobiprostone, lubiprostone	1.00
trials ClinicalTrials.gov	2 Parkinson's trials, 1 stopped	0.60
literature PubMed	1 Parkinson's papers of 169	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 9732

receipt 9740: CLCN2 in dopamine neurons, braak

power: full sample -0.29 (p 0.243, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.32 (p 0.198, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.111, n 18). could be the mix.
skeptic: leave-one-out range -0.37 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.243, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLCN2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 9739: CLCN2 in astrocytes, braak

power: full sample -0.37 (p 0.135, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.33 (p 0.179, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.26 (p 0.289, n 18). could be the mix.
skeptic: leave-one-out range -0.54 to -0.28, sign flips 0; without severely affected donors -0.37 (p 0.135, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLCN2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts